Skip to main content
Atrás
Watch Compare

Ernexa Therapeutics Inc.

Calidad de datos: 100%
También listada como ERNAW Nasdaq
ERNA
Nasdaq Manufacturing Chemicals
$0.21
▼ $0.01 (-6.36%)
Cap. Mercado: 6.05 M
Precio
$0.21
Cap. Mercado
6.05 M
Rango del Día
$0.21 — $0.22
Rango de 52 Semanas
$0.18 — $4.05
Volumen
214,540
Apertura $0.21
Promedio 50D / 200D
$0.44
53.54% below
Promedio 50D / 200D
$1.23
83.20% below

Quick Summary

Puntos Clave

Negative free cash flow of -7.05 M
Capital efficient — spends only 6.36% of revenue on capex

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)0.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-351.48%
Below sector avg (-53.41%)
ROIC-164.31%
Net Margin-2419.93%
Op. Margin-1601.20%

Seguridad

Debt / Equity
N/A
Current Ratio1.58
Interest Coverage-423.59

Valoración

PE (TTM)
-0.43
Above sector avg (-1.48)
P/B Ratio1.70
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -0.4 -1.5
P/B 1.7 1.6
ROE % -351.5 -53.4
Net Margin % -2419.9 -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0.00% Revenue Growth (3Y) 192.55%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 582,000.0 Net Income (TTM) -14.08 M
ROE -351.48% ROA -204.77%
Gross Margin 83.51% Operating Margin -1601.20%
Net Margin -2419.93% Free Cash Flow (TTM) -7.05 M
ROIC -164.31% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1.58
Interest Coverage -423.59 Asset Turnover 0.08
Working Capital 1.24 M Tangible Book Value 1.53 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.43 Forward P/E N/A
P/B Ratio 1.70 P/S Ratio 10.40
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -116.55%
Market Cap 6.05 M Enterprise Value 6.05 M
Per Share
EPS (Diluted TTM) -2.24 Revenue / Share 0.02
FCF / Share -0.24 OCF / Share -0.24
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 6.36% FCF Conversion 50.09%
SBC-Adj. FCF -8.62 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 582,000.0 582,000.0 68,000.0 — —
Net Income -14.08 M -44.54 M -21.67 M -24.58 M -122.31 M
EPS (Diluted) -2.24 -3.26 -4.08 -8.06 -2.82
Gross Profit 486,000.0 486,000.0 -168,000.0 — —
Operating Income -9.32 M -15.67 M -21.14 M -33.22 M -113.55 M
EBITDA — — — — —
R&D Expenses — — — — —
SG&A Expenses — — — — —
D&A 65,000.0 139,000.0 84,000.0 161,000.0 117,000.0
Interest Expense 22,000.0 174,000.0 614,000.0 — —
Income Tax -45,000.0 30,000.0 -3,000.0 45,000.0 5,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 5.83 M 5.27 M 49.13 M 22.28 M 32.43 M
Total Liabilities 3.43 M 3.57 M 46.90 M 10.17 M 25.93 M
Shareholders' Equity 2.40 M 1.70 M 2.23 M 12.11 M 6.50 M
Total Debt — — — — —
Cash & Equivalents — 1.73 M 7.58 M 11.45 M —
Current Assets 3.13 M 2.35 M 9.60 M 13.68 M 18.77 M
Current Liabilities 3.11 M 2.94 M 6.57 M 7.65 M 3.68 M